0001558370-21-011781.txt : 20210816 0001558370-21-011781.hdr.sgml : 20210816 20210816111852 ACCESSION NUMBER: 0001558370-21-011781 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20210816 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210816 DATE AS OF CHANGE: 20210816 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ReShape Lifesciences Inc. CENTRAL INDEX KEY: 0001427570 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37897 FILM NUMBER: 211175597 BUSINESS ADDRESS: STREET 1: 1001 CALLE AMANECER CITY: SAN CLEMENTE STATE: CA ZIP: 92673 BUSINESS PHONE: 949-429-6680 MAIL ADDRESS: STREET 1: 1001 CALLE AMANECER CITY: SAN CLEMENTE STATE: CA ZIP: 92673 FORMER COMPANY: FORMER CONFORMED NAME: OBALON THERAPEUTICS INC DATE OF NAME CHANGE: 20080220 8-K 1 rsls-20210816x8k.htm 8-K
0001427570false00014275702021-08-162021-08-16

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 16, 2021

RESHAPE LIFESCIENCES INC.

(Exact name of registrant as specified in its charter)

Delaware

1-37897

26-1828101

(State or other jurisdiction of incorporation)

(Commission File Number)

(I.R.S. Employer Identification Number)

1001 Calle Amanecer
San Clemente, CA

92673

(Address of principal executive offices)

(Zip Code)

(949) 429-6680

(Registrant’s telephone number, including area code)

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Class

    Trading Symbol

Name of Exchange on which Registered

Common stock, $0.001 par value per share

RSLS

The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

Item 2.02           Results of Operations and Financial Condition.

On August 16, 2021 ReShape Lifesciences Inc. (the “Company”) issued a press release announcing its financial results for the three and six months ended June 30, 2021. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information furnished herewith pursuant to Item 2.02 of this Current Report and in Exhibit 99.1 hereto is being “furnished” in accordance with General Instruction B.2 of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01           Financial Statements and Exhibits.

(d)Exhibits.

Exhibit No.

Description

99.1

Press Release dated August 16, 2021

104

Cover Page Interactive Data File (embedded with inline XBRL document

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

RESHAPE LIFESCIENCES INC.

By:

/s/ Tom Stankovich

Tom Stankovich

Chief Financial Officer

Dated: August 16, 2021

EX-99.1 2 rsls-20210816xex99d1.htm EX-99.1

Graphic

Exhibit 99.1

ReShape Reports Second Quarter 2021 Financial Results and Provides Business Update

Webinar to follow at 8:30 a.m. today

San Clemente, CA August 16, 2021 — ReShape Lifesciences Inc. (NASDAQ: RSLS), a leading developer and distributor of minimally invasive medical devices to treat obesity and metabolic diseases, today reported its financial and operational results for the three months ended June 30, 2021.

Recent Highlights and Accomplishments

Successfully completed merger with Obalon Therapeutics positioning ReShape as major leader in weight loss market
Began trading June 16 on Nasdaq Capital Market under ticker RSLS
Transition of Lap-Band manufacturing from previous owners to US-based manufacturer under our operational oversight
Completed funding round raising gross proceed of $46 million; eliminated debt overhang; removed any and all liens against our assets and now leveraging stronger balance sheet
Introduced ReShape MarketplaceTM; digital health solution adding to proprietary ecosystem of weight loss products
Witnessed an increase in Lap-Band procedures among practices

Bart Bandy, President and Chief Executive Officer of ReShape Lifesciences, commented, “As indicated by our preliminary results, the second quarter proved to be monumental for the Company. During this period, we completed our highly anticipated merger with Obalon Therapeutics, increased visibility in the financial markets by listing on the Nasdaq and bolstered our diverse product portfolio with the launch of our online wellness hub, ReShape MarketPlace. In addition, we restructured our balance sheet closing a $46 million funding round which has now enabled our team to focus on further growth initiatives within the weight loss industry.”

Mr. Bandy continued, “Additionally, we proactively addressed operational efficiency concerns by shifting the manufacturing of the Lap-Band to a US-based firm. We believe this series of positive events clearly indicate a path of positive transformation for ReShape.”


Graphic

Second Quarter 2021 Financial Results

Revenue for the three months ended June 30, 2021, was $3.5 million compared to $1.7 million in revenue for the three months ended June 30, 2020. The $1.8 million increase was primarily due to greater US sales. Revenues grew 10% from the 1st Quarter 2021 representing increases in both US and OUS revenues.

Gross profit for the second quarter of 2021 was $2.1 million compared to $0.8 million for the three months ended June 30, 2020.

Sales and marketing expenses for the three months ended June 30, 2021 were $1.4 million compared to $0.8 million for the three months ended June 30, 2020.

General and administrative expenses were $4.3 million for the second quarter of 2021 compared to $2.5 million for the three months ended June 30, 2020.

Research and development expenses were $0.1 million for the second quarter of 2021 compared to $0.5 million for the three months ended June 30, 2020.

Total operating expenses were $5.9 million for the second quarter of 2021 compared to $3.8 million for the three months ended June 30, 2020.

Non-GAAP adjusted EBITDA loss was $1.2 million for the second quarter of 2021 compared to a loss of $2.1 million for the three months ended June 30, 2020.

Cash and cash equivalents and restricted cash were $40.2 million as of June 30, 2021.

Webinar Information

Management will post a webinar discussing ReShape's financial and operational results today at 8:30 a.m. ET. The link to the webinar is here and will be available on the Investor Relations page of the ReShape Lifesciences, Inc. website, https://ir.reshapelifesciences.com/.

About ReShape Lifesciences, Inc. 
ReShape Lifesciences™ is America's premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band® Program provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The ReShape Vest™ System is an investigational (outside the U.S.) minimally invasive, laparoscopically implanted medical device that wraps around the stomach, emulating the gastric volume reduction effect of conventional weight-loss surgery. It helps enable rapid weight loss in obese and morbidly obese patients without permanently changing patient anatomy. reshapecare ™ is a virtual weight-management program that supports lifestyle changes for all weight-loss patients led by board certified health coaches to help them keep the weight off over time. The recently launched ReShape Marketplace™ is an online collection of quality wellness products curated for all consumers to help them achieve their health goals.

Forward-Looking Safe Harbor Statement:

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those discussed due to known and unknown risks, uncertainties, and other factors. These and additional risks and uncertainties are described more fully in the company’s filings with the Securities and Exchange Commission, including those factors identified as “risk factors” in our Annual Report on Form 10-K and in our subsequent Quarterly Report on Form 10-Q.


Graphic

Non-GAAP Disclosures

In addition to the financial information prepared in conformity with GAAP, we provide certain historical non-GAAP financial information. Management believes that these non-GAAP financial measures assist investors in making comparisons of period-to-period operating results and that, in some respects, these non-GAAP financial measures are more indicative of the Company's ongoing core operating performance than their GAAP equivalents.

Management believes that the presentation of this non-GAAP financial information provides investors with greater transparency and facilitates comparison of operating results across a broad spectrum of companies with varying capital structures, compensation strategies, derivative instruments, and amortization methods, which provides a more complete understanding of our financial performance, competitive position, and prospects for the future. However, the non-GAAP financial measures presented in this Form 10-K have certain limitations in that they do not reflect all of the costs associated with the operations of our business as determined in accordance with GAAP. Therefore, investors should consider non-GAAP financial measures in addition to, and not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. Further, the non-GAAP financial measures presented by the Company may be different from similarly named non-GAAP financial measures used by other companies.

Adjusted EBITDA

Management uses Adjusted EBITDA in its evaluation of the Company's core results of operations and trends between fiscal periods and believes that these measures are important components of its internal performance measurement process. Adjusted EBITDA is defined as net loss before interest, taxes, depreciation and amortization, stock-based compensation, changes in fair value of liability warrants and other one-time costs. Management uses Adjusted EBITDA in its evaluation of the Company's core results of operations and trends between fiscal periods and believes that these measures are important components of its internal performance measurement process. Therefore, investors should consider non-GAAP financial measures in addition to, and not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. Further, the non-GAAP financial measures presented by the Company may be different from similarly named non-GAAP financial measures used by other companies.

CONTACTS: 
ReShape Lifesciences Investor Contact: 
Thomas Stankovich
Chief Financial Officer
949-276-6042
ir@ReShapeLifesci.com

Investor Contacts: 
Daniel Kontoh-Boateng
Assistant Vice President
The Ruth Group
646-536-7019
dboateng@theruthgroup.com


Graphic

RESHAPE LIFESCIENCES INC.

Condensed Consolidated Balance Sheets

(dollars in thousands, except per share amounts; unaudited)

June 30, 

December 31, 

    

2021

    

2020

ASSETS

Current assets:

Cash and cash equivalents

$

40,163

 

$

2,957

Restricted cash

50

50

Accounts and other receivables

 

3,422

 

 

2,620

Inventory

 

2,894

 

 

2,244

Deferred stock issuance costs*

17,705

Prepaid expenses and other current assets

 

1,371

 

 

1,073

Total current assets

 

65,605

 

 

8,944

Property and equipment, net

 

1,588

 

 

584

Operating lease right-of-use assets

632

465

Other intangible assets, net

28,924

27,022

Goodwill

21,623

Other assets

 

1,628

 

 

46

Total assets

$

120,000

 

$

37,061

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities:

Accounts payable

$

3,095

 

$

3,655

Accrued and other liabilities*

 

53,333

 

 

3,630

Warranty liability, current

468

397

Debt, current portion, net of deferred financing costs

2,936

3,609

Operating lease liabilities, current

664

314

Total current liabilities

 

60,496

 

 

11,605

Debt, noncurrent portion

9,168

Operating lease liabilities, noncurrent

163

Warranty liability, noncurrent

732

1,022

Deferred income taxes

615

615

Other liabilities

38

Total liabilities

61,881

 

22,573

Commitments, contingencies and subsequent events

Stockholders’ equity:

Preferred stock:

Series B convertible preferred stock

Series C convertible preferred stock

1

Common stock

 

8

 

 

6

Additional paid-in capital

 

581,823

 

 

529,429

Accumulated deficit

 

(523,603)

 

 

(514,827)

Accumulated other comprehensive loss

(109)

(121)

Total stockholders’ equity

 

58,119

 

 

14,488

Total liabilities and stockholders’ equity

$

120,000

 

$

37,061

* Relates to the shares not issued in conjunction with the June 28, 2021 warrant exercise agreement, prior to the quarter ended June 30, 2021. Since the shares are in abeyance, an accrual of $43.2 million was recorded, along with $17.7 million in deferred issuance costs. This will be recognized against equity during the quarter ended September 30, 2021.


Graphic

RESHAPE LIFESCIENCES INC.

Condensed Consolidated Statements of Operations

(dollars in thousands, except per share amounts; unaudited)

Three Months Ended June 30, 

Six Months Ended June 30, 

2021

2020

    

2021

2020

Revenue

$

3,529

$

1,702

$

6,750

$

4,491

Cost of revenue

1,376

 

865

 

2,314

 

2,150

Gross profit

2,153

 

837

 

4,436

 

2,341

Operating expenses:

Sales and marketing

1,441

 

831

 

2,691

 

2,285

General and administrative

4,311

2,539

7,031

5,375

Research and development

103

 

465

 

674

 

1,761

Total operating expenses

5,855

 

3,835

 

10,396

 

9,421

Operating loss

(3,702)

 

(2,998)

 

(5,960)

 

(7,080)

Other expense (income), net:

Interest expense, net

172

789

771

893

Loss on extinguishment of debt, net

101

2,061

Loss (gain) on foreign currency exchange, net

(101)

(133)

(69)

10

Loss before income tax provision

(3,874)

(3,654)

(8,723)

(7,983)

Income tax expense (benefit)

28

(50)

53

(68)

Net loss

$

(3,902)

$

(3,604)

$

(8,776)

$

(7,915)

Net loss per share - basic and diluted:

Net loss per share - basic and diluted

$

(0.47)

$

(0.52)

$

(1.11)

$

(1.15)

Shares used to compute basic and diluted net loss per share

8,226,144

 

6,911,497

 

7,928,702

 

6,885,368

The following table contains a reconciliation of non-GAAP net loss to GAAP net loss attributable to common stockholders for the three and six months ended June 30, 2021 and 2020 (in thousands):

Three Months Ended June 30, 

Six Months Ended June 30, 

2021

2020

2021

2020

GAAP net loss

$

(3,902)

$

(3,604)

$

(8,776)

$

(7,915)

Adjustments:

Interest expense, net

172

789

771

893

Income tax expense (benefit)

28

(50)

53

(68)

Depreciation and amortization

450

418

868

838

Stock-based compensation expense

(364)

347

(263)

774

Loss on extinguishment of debt, net

101

2,061

Professional fees incurred in connection with the Obalon merger

2,277

2,277

Non-GAAP loss

$

(1,238)

$

(2,100)

$

(3,009)

$

(5,478)


GRAPHIC 3 rsls-20210816xex99d1001.jpg GRAPHIC begin 644 rsls-20210816xex99d1001.jpg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end EX-101.SCH 4 rsls-20210816.xsd EX-101.SCH 00090 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 rsls-20210816_lab.xml EX-101.LAB EX-101.PRE 6 rsls-20210816_pre.xml EX-101.PRE XML 7 rsls-20210816x8k_htm.xml IDEA: XBRL DOCUMENT 0001427570 2021-08-16 2021-08-16 0001427570 false 8-K 2021-08-16 RESHAPE LIFESCIENCES INC. DE 1-37897 26-1828101 1001 Calle Amanecer San Clemente CA 92673 949 429-6680 false false false false Common stock, $0.001 par value per share RSLS NASDAQ false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Cover
Aug. 16, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 16, 2021
Entity Registrant Name RESHAPE LIFESCIENCES INC.
Entity Incorporation, State or Country Code DE
Entity File Number 1-37897
Entity Tax Identification Number 26-1828101
Entity Address, Address Line One 1001 Calle Amanecer
Entity Address, City or Town San Clemente
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92673
City Area Code 949
Local Phone Number 429-6680
Entity Central Index Key 0001427570
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, $0.001 par value per share
Trading Symbol RSLS
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 00090 - Document - Cover Sheet http://reshapelifesciences.com/role/DocumentCover Cover Cover 1 false false All Reports Book All Reports rsls-20210816x8k.htm rsls-20210816.xsd rsls-20210816_lab.xml rsls-20210816_pre.xml rsls-20210816xex99d1.htm http://xbrl.sec.gov/dei/2020-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "rsls-20210816x8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "rsls-20210816x8k.htm" ] }, "labelLink": { "local": [ "rsls-20210816_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "rsls-20210816_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "rsls-20210816.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "rsls", "nsuri": "http://reshapelifesciences.com/20210816", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "rsls-20210816x8k.htm", "contextRef": "Duration_8_16_2021_To_8_16_2021_YkQEF3wcnk2Sbd-kgdQbfg", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Cover", "role": "http://reshapelifesciences.com/role/DocumentCover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "rsls-20210816x8k.htm", "contextRef": "Duration_8_16_2021_To_8_16_2021_YkQEF3wcnk2Sbd-kgdQbfg", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://reshapelifesciences.com/role/DocumentCover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://reshapelifesciences.com/role/DocumentCover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://reshapelifesciences.com/role/DocumentCover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://reshapelifesciences.com/role/DocumentCover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://reshapelifesciences.com/role/DocumentCover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://reshapelifesciences.com/role/DocumentCover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://reshapelifesciences.com/role/DocumentCover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://reshapelifesciences.com/role/DocumentCover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://reshapelifesciences.com/role/DocumentCover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://reshapelifesciences.com/role/DocumentCover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://reshapelifesciences.com/role/DocumentCover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://reshapelifesciences.com/role/DocumentCover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://reshapelifesciences.com/role/DocumentCover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://reshapelifesciences.com/role/DocumentCover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://reshapelifesciences.com/role/DocumentCover" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://reshapelifesciences.com/role/DocumentCover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://reshapelifesciences.com/role/DocumentCover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://reshapelifesciences.com/role/DocumentCover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://reshapelifesciences.com/role/DocumentCover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://reshapelifesciences.com/role/DocumentCover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://reshapelifesciences.com/role/DocumentCover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://reshapelifesciences.com/role/DocumentCover" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0001558370-21-011781-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-21-011781-xbrl.zip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end